85 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author최한곤-
dc.date.accessioned2018-02-22T00:29:15Z-
dc.date.available2018-02-22T00:29:15Z-
dc.date.issued2015-09-
dc.identifier.citationJOURNAL OF CONTROLLED RELEASE, V. 214, Page. 30-39en_US
dc.identifier.issn0168-3659-
dc.identifier.issn1873-4995-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168365915300262-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/39286-
dc.description.abstractThe key to making a practicable hydrogel for pharmaceutical or medical purposes is to endow it with relevant properties, i.e., facile fabrication, gelation time-controllability, and in situ injectability given a firm basis for safety/biocompatibility. Here, the authors describe an in situ gelling, injectable, albumin-cross-linked polyethylene glycol (PEG) hydrogel that was produced using a thiol-maleimide reaction. This hydrogel consists of two biocompatible components, namely, thiolated human serum albumin and 4-arm PEG(20k)-maleimide, and can be easily fabricated and gelled in situ within 60 s by simply mixing its two components. In addition, the gelation time of this system is controllable in the range 15 s to 5 min. This hydrogel hardly interacted with an apoptotic TRAIL protein, ensuring suitable release profiles that maximize therapeutic efficacy. Specifically, tumors (volume: 278.8 mm(3)) in Mia Paca-2 cell-xenografted BALB/c nu/nu mice treated with the TRAIL-loaded HSA-PEG hydrogel were markedly smaller than mice treated with the hydrogel prepared via an amine-N-hydroxysuccinimide reaction or non-treated mice (1275.5 mm(3) and 1816.5 mm(3), respectively). We believe that this hydrogel would be a new prototype of locally injectable sustained-release type anti-cancer agents, and furthermore offers practical convenience for a doctor and universal applicability for a variety of therapeutic proteins. (C) 2015 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipThis research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (#2014002133).en_US
dc.language.isoen_USen_US
dc.publisherELSEVIER SCIENCE BVen_US
dc.subjectHydrogelen_US
dc.subjectPolyethylene glycolen_US
dc.subjectAlbuminen_US
dc.subjectIn situ formationen_US
dc.subjectTNF-related apoptosis-inducing liganden_US
dc.subjectPancreatic canceren_US
dc.subjectHUMAN SERUM-ALBUMINen_US
dc.subjectLIGAND TRAILen_US
dc.subjectCRYSTAL-STRUCTUREen_US
dc.subjectMOUSE SKINen_US
dc.subjectDELIVERYen_US
dc.subjectRELEASEen_US
dc.subjectDRUGen_US
dc.subjectPEGYLATIONen_US
dc.subjectCHITOSANen_US
dc.subjectCARRIERen_US
dc.titleIn situ facile-forming PEG cross-linked albumin hydrogels loaded with an apoptotic TRAIL proteinen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jconrel.2015.07.012-
dc.relation.page30-39-
dc.relation.journalJOURNAL OF CONTROLLED RELEASE-
dc.contributor.googleauthorKim, IS-
dc.contributor.googleauthorChoi, JS-
dc.contributor.googleauthorLee, S.H-
dc.contributor.googleauthorByeon, HJ-
dc.contributor.googleauthorLee, ES-
dc.contributor.googleauthorShin, BS-
dc.contributor.googleauthorChoi, HG-
dc.contributor.googleauthorLee, KC-
dc.contributor.googleauthorYoun, YS-
dc.relation.code2015002880-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhangon-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE